Overview
NTHI market data
Price History
NTHI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.01 – $12.99 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $95.2 · P/S 1,189.62.
Company news
8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)SEC EDGAR · Jul 15, 2026, 1:15 PM
NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July MeetingBenzinga · Jul 15, 2026, 1:03 PM
NeOnc Technologies Granted Investigational New Drug Status From Abu Dhabi's Department Of Health For NEO100 To Treat Non-Invasive Nose-To-Brain DeliveryBenzinga · Jun 23, 2026, 1:10 PM
NeOnc Technologies Proceeding Ahead With Pipeline Of Therapies After Receiving Department of Health – Abu Dhabi Authorization For Its Investigational New Drug For NEO212 To Treat Aggressive Brain Tumors, Including GlioblastomaBenzinga · Jun 17, 2026, 1:35 PM
NeOnc Announces Abu Dhabi DOH Grants IND Status For NEO212, Orally Administered Perillyl Alcohol-Temozolomide Carbamate Conjugate Being Developed For Patients With Aggressive Brain TumorsBenzinga · Jun 16, 2026, 1:10 PM
BTIG Reiterates Buy on NeOnc Technologies Hldgs, Maintains $15 Price TargetBenzinga · May 26, 2026, 10:26 AM
Alliance Global Partners Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $13Benzinga · May 19, 2026, 2:05 PM
Maxim Group Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $20Benzinga · May 18, 2026, 7:00 PM
NeOnc Technologies Q1 EPS $(0.38) Misses $(0.17) EstimateBenzinga · May 18, 2026, 1:10 PM